The cost of biopharmaceutical R&D: is biotech different?
Author
Abstract
Suggested Citation
DOI: 10.1002/mde.1360
Download full text from publisher
References listed on IDEAS
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Fumio Teramae & Tomohiro Makino & Shintaro Sengoku & Yeongjoo Lim & Takashi Natori & Kota Kodama, 2020. "Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth," Sustainability, MDPI, vol. 12(21), pages 1-13, October.
- Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
- Wu, Qiang & He, Qile, 2020. "DIY Laboratories and business innovation ecosystems: The case of pharmaceutical industry," Technological Forecasting and Social Change, Elsevier, vol. 161(C).
- Ernst R. Berndt & Joseph P. Newhouse, 2010.
"Pricing and Reimbursement in U.S. Pharmaceutical Markets,"
NBER Working Papers
16297, National Bureau of Economic Research, Inc.
- Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
- Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
- Snyder, Christopher M. & Hoyt, Kendall & Gouglas, Dimitrios, 2023.
"An optimal mechanism to fund the development of vaccines against emerging epidemics,"
Journal of Health Economics, Elsevier, vol. 91(C).
- Christopher M. Snyder & Kendall Hoyt & Dimitrios Gouglas, 2022. "An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics," NBER Working Papers 30619, National Bureau of Economic Research, Inc.
- Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022.
"The economics of medical procedure innovation,"
Journal of Health Economics, Elsevier, vol. 81(C).
- David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
- Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2014. "Public funds and local biotechnology firm creation," Research Policy, Elsevier, vol. 43(1), pages 121-137.
- Hassanzadeh, Farhad & Modarres, Mohammad & Nemati, Hamid R. & Amoako-Gyampah, Kwasi, 2014. "A robust R&D project portfolio optimization model for pharmaceutical contract research organizations," International Journal of Production Economics, Elsevier, vol. 158(C), pages 18-27.
- Giovanna Lo Nigro & Azzurra Morreale & Lorenzo Abbate, 2016. "An Open Innovation Decision Support System to Select a Biopharmaceutical R&D Portfolio," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 37(6), pages 392-406, September.
- Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
- Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
- Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).
- Wang, Kung-Jeng & Lestari, Yuliani Dwi, 2013. "Firm competencies on market entry success: Evidence from a high-tech industry in an emerging market," Journal of Business Research, Elsevier, vol. 66(12), pages 2444-2450.
- Arisa Djurian & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs," Sustainability, MDPI, vol. 12(14), pages 1-14, July.
- Mazzola, Erica & Perrone, Giovanni & Kamuriwo, Dzidziso Samuel, 2015. "Network embeddedness and new product development in the biopharmaceutical industry: The moderating role of open innovation flow," International Journal of Production Economics, Elsevier, vol. 160(C), pages 106-119.
- Bae, Joonhyung & Ozmel, Umit, 2024. "The interplay between product development failures and alliance portfolio properties in the formation of exploration versus exploitation alliances," Journal of Business Research, Elsevier, vol. 177(C).
- Hoenen, Sebastian & Kolympiris, Christos & Schoenmakers, Wilfred & Kalaitzandonakes, Nicholas, 2014. "The diminishing signaling value of patents between early rounds of venture capital financing," Research Policy, Elsevier, vol. 43(6), pages 956-989.
- Thakur–Wernz, Pooja & Wernz, Christian, 2022. "Impact of stronger intellectual property rights regime on innovation: Evidence from de alio versus de novo Indian bio-pharmaceutical firms," Journal of Business Research, Elsevier, vol. 138(C), pages 457-473.
- Adam Jørring & Andrew W Lo & Tomas J Philipson & Manita Singh & Richard T Thakor, 2022.
"Sharing R&D Risk in Healthcare via FDA Hedges [Bank lines of credit as contingent liquidity: Covenant violations and their implications],"
The Review of Corporate Finance Studies, Society for Financial Studies, vol. 11(4), pages 880-922.
- Adam Jørring & Andrew W. Lo & Tomas J. Philipson & Manita Singh & Richard T. Thakor, 2017. "Sharing R&D Risk in Healthcare via FDA Hedges," NBER Working Papers 23344, National Bureau of Economic Research, Inc.
- Yu, Xinning & Lan, Yanfei & Zhao, Ruiqing, 2021. "Strategic green technology innovation in a two-stage alliance: Vertical collaboration or co-development?," Omega, Elsevier, vol. 98(C).
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
- Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2015. "Location choice of academic entrepreneurs: Evidence from the US biotechnology industry," Journal of Business Venturing, Elsevier, vol. 30(2), pages 227-254.
- Williams, David R., 2013. "Human and financial capital as determinants of biopharmaceutical IPO de-listings," Journal of Business Research, Elsevier, vol. 66(12), pages 2612-2618.
- Colvin, Matthew & Maravelias, Christos T., 2011. "R&D pipeline management: Task interdependencies and risk management," European Journal of Operational Research, Elsevier, vol. 215(3), pages 616-628, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
- Holger Patzelt & Dean A. Shepherd, 2009. "Strategic Entrepreneurship at Universities: Academic Entrepreneurs’ Assessment of Policy Programs," Entrepreneurship Theory and Practice, , vol. 33(1), pages 319-340, January.
- Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
- Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.
- Dosis, Anastasios & Muthoo, Abhinay, 2019.
"Experimentation in Dynamic R&D Competition,"
CRETA Online Discussion Paper Series
52, Centre for Research in Economic Theory and its Applications CRETA.
- Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," The Warwick Economics Research Paper Series (TWERPS) 1214, University of Warwick, Department of Economics.
- Anastasios, Dosis & Abhinay, Muthoo, 2019. "Experimentation in Dynamic R&D Competition," ESSEC Working Papers WP1901, ESSEC Research Center, ESSEC Business School.
- Anastasios Dosis & Abhinay Muthoo, 2019. "Experimentation in Dynamic R&D Competition," Working Papers hal-02102518, HAL.
- Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
- Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Garavaglia Christian & Malerba Franco & Orsenigo Luigi & Pezzoni Michele, 2014.
"Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data,"
Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 234(2-3), pages 274-298, April.
- Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2014. "Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data," Post-Print halshs-01074524, HAL.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002.
"Returns on R&D for 1990s New Drug Introductions,"
Working Papers
02-21, Duke University, Department of Economics.
- Henry Grabowski & John Vernon & Joseph DiMasi, 2003. "Returns on R&D for 1990s New Drug Introductions," Levine's Working Paper Archive 618897000000000666, David K. Levine.
- Ming Liu & Sumner LaCroix, 2011.
"The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries,"
Working Papers
201116, University of Hawaii at Manoa, Department of Economics.
- Ming Liu & Sumner La Croix, 2014. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201407, University of Hawaii at Manoa, Department of Economics.
- Ming Liu & Sumner La Croix, 2014. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 2014-12, University of Hawaii Economic Research Organization, University of Hawaii at Manoa.
- Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018.
"Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?,"
Risks, MDPI, vol. 6(3), pages 1-27, July.
- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Post-Print hal-01571937, HAL.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Waters, James, 2014. "Introduction of innovations during the 2007-8 financial crisis: US companies compared with universities," MPRA Paper 59016, University Library of Munich, Germany.
- Wolfgang Hein & Lars Kohlmorgen, 2005.
"Global Health Governance: Conflicts on Global Social Rights,"
HEW
0509001, University Library of Munich, Germany.
- Hein, Wolfgang & Kohlmorgen, Lars, 2005. "Global Health Governance: Conflicts on Global Social Rights," GIGA Working Papers 7, GIGA German Institute of Global and Area Studies.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Gnanaraj Chellaraj & Keith E. Maskus & Aaditya Mattoo, 2008. "The Contribution of International Graduate Students to US Innovation," Review of International Economics, Wiley Blackwell, vol. 16(3), pages 444-462, August.
- Jommi, Claudio & Paruzzolo, Silvia, 2007. "Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study," Health Policy, Elsevier, vol. 81(1), pages 117-130, April.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:469-479. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/7976 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.